Published in Biochem Biophys Res Commun on June 25, 2004
Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest (2005) 1.49
Transcriptome Analysis Reveals Regulation of Gene Expression for Lipid Catabolism in Young Broilers by Butyrate Glycerides. PLoS One (2016) 1.38
Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest (2005) 1.37
Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families. J Biol Chem (2008) 1.26
Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target. J Lipids (2011) 1.09
Give me A5 for lipoprotein hydrolysis! J Clin Invest (2005) 1.07
Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol (2005) 1.02
APOA5 genotype modulates 2-y changes in lipid profile in response to weight-loss diet intervention: the Pounds Lost Trial. Am J Clin Nutr (2012) 1.00
Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice. J Lipid Res (2007) 0.98
APOA5 gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerides in a Mediterranean population. J Nutr (2011) 0.96
Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans. Arterioscler Thromb Vasc Biol (2006) 0.95
The ins (cell) and outs (plasma) of apolipoprotein A-V. J Lipid Res (2008) 0.95
Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion. J Lipid Res (2010) 0.92
A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice. J Pharmacol Exp Ther (2014) 0.90
FXR an emerging therapeutic target for the treatment of atherosclerosis. J Cell Mol Med (2010) 0.89
Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approach. J Obes (2011) 0.89
Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis. Metabolism (2009) 0.88
Apoprotein A-V: an important regulator of triglyceride metabolism. J Inherit Metab Dis (2008) 0.87
An APOA5 3' UTR variant associated with plasma triglycerides triggers APOA5 downregulation by creating a functional miR-485-5p binding site. Am J Hum Genet (2014) 0.86
The APOA5 Trp19 allele is associated with metabolic syndrome via its association with plasma triglycerides. BMC Med Genet (2008) 0.86
Determinants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans. J Intern Med (2008) 0.85
Synthesis analysis of regression models with a continuous outcome. Stat Med (2009) 0.84
Allelic drop-out may occur with a primer binding site polymorphism for the commonly used RFLP assay for the -1131T>C polymorphism of the Apolipoprotein AV gene. Lipids Health Dis (2006) 0.83
Apolipoprotein A5 and lipoprotein lipase interact to modulate anthropometric measures in Hispanics of Caribbean origin. Obesity (Silver Spring) (2009) 0.83
Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B (2015) 0.81
ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content. J Lipid Res (2014) 0.80
The association between APOA5 haplotypes and plasma lipids is not modified by energy or fat intake: the Czech HAPIEE study. Nutr Metab Cardiovasc Dis (2013) 0.79
Interaction of dietary fat intake with APOA2, APOA5 and LEPR polymorphisms and its relationship with obesity and dyslipidemia in young subjects. Lipids Health Dis (2015) 0.78
Apolipoprotein A-V deficiency enhances chylomicron production in lymph fistula mice. Am J Physiol Gastrointest Liver Physiol (2015) 0.77
GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells. World J Gastroenterol (2014) 0.76
ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency. J Lipid Res (2008) 0.76
Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers. Pathology (2015) 0.75
Apolipoprotein A-V is present in bile and its secretion increases with lipid absorption in Sprague-Dawley rats. Am J Physiol Gastrointest Liver Physiol (2015) 0.75
Association of G894T eNOS, 4G/5G PAI and T1131C APOA5 polymorphisms with susceptibility to myocardial infarction in Morocco. Meta Gene (2016) 0.75
Genetic Variants Associated with Gestational Hypertriglyceridemia and Pancreatitis. PLoS One (2015) 0.75
Genetics of non-conventional lipoprotein fractions. Curr Genet Med Rep (2015) 0.75
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature (2009) 18.38
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet (2007) 13.78
Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am J Hum Genet (2007) 10.92
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
The amphioxus genome and the evolution of the chordate karyotype. Nature (2008) 8.03
VISTA Enhancer Browser--a database of tissue-specific human enhancers. Nucleic Acids Res (2006) 7.04
Metagenomic discovery of biomass-degrading genes and genomes from cow rumen. Science (2011) 6.93
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Genomic views of distant-acting enhancers. Nature (2009) 6.27
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (2006) 5.67
Medical sequencing at the extremes of human body mass. Am J Hum Genet (2007) 5.61
Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest (2008) 5.05
Deletion of ultraconserved elements yields viable mice. PLoS Biol (2007) 4.81
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet (2006) 4.68
Massively parallel functional dissection of mammalian enhancers in vivo. Nat Biotechnol (2012) 4.51
ChIP-Seq identification of weakly conserved heart enhancers. Nat Genet (2010) 4.32
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
Disruption of an AP-2alpha binding site in an IRF6 enhancer is associated with cleft lip. Nat Genet (2008) 4.04
Close sequence comparisons are sufficient to identify human cis-regulatory elements. Genome Res (2006) 3.92
Human-specific gain of function in a developmental enhancer. Science (2008) 3.84
Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature (2010) 3.77
Ultraconservation identifies a small subset of extremely constrained developmental enhancers. Nat Genet (2008) 3.55
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest (2006) 3.48
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet (2007) 3.47
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care (2006) 3.37
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest (2003) 3.09
The amphioxus genome illuminates vertebrate origins and cephalochordate biology. Genome Res (2008) 3.04
Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc Natl Acad Sci U S A (2013) 2.93
Large-scale discovery of enhancers from human heart tissue. Nat Genet (2011) 2.70
Combinatorial regulation of endothelial gene expression by ets and forkhead transcription factors. Cell (2008) 2.60
Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet (2009) 2.57
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38
A high-resolution enhancer atlas of the developing telencephalon. Cell (2013) 2.34
Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes (2005) 2.32
The DNA sequence and biology of human chromosome 19. Nature (2004) 2.29
Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet (2002) 2.27
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res (2004) 2.16
Fine tuning of craniofacial morphology by distant-acting enhancers. Science (2013) 2.16
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol (2006) 2.15
Increased ABCA1 activity protects against atherosclerosis. J Clin Invest (2002) 2.13
Homotypic clusters of transcription factor binding sites are a key component of human promoters and enhancers. Genome Res (2010) 2.12
Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem (2005) 2.07
Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol (2005) 2.06
Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha. Gastroenterology (2008) 2.06
Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis (2003) 2.02
C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol (2003) 1.99
Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation (2004) 1.98
Phylo-VISTA: interactive visualization of multiple DNA sequence alignments. Bioinformatics (2004) 1.97
Genome resequencing reveals multiscale geographic structure and extensive linkage disequilibrium in the forest tree Populus trichocarpa. New Phytol (2012) 1.88
Dlx1&2-dependent expression of Zfhx1b (Sip1, Zeb2) regulates the fate switch between cortical and striatal interneurons. Neuron (2013) 1.87
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem (2005) 1.85
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest (2002) 1.80
Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta (2007) 1.79
Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci (2003) 1.78
The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation. J Biol Chem (2003) 1.76
Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties. Circ Res (2004) 1.72
A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet (2009) 1.71
Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription. J Lipid Res (2002) 1.71
Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med (2005) 1.69
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol (2005) 1.68
Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol (2002) 1.63
Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha. Arterioscler Thromb Vasc Biol (2005) 1.63
Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes (2004) 1.63
Atherogenic lipoprotein particles in atherosclerosis. Circulation (2004) 1.63
Lack of MEF2A mutations in coronary artery disease. J Clin Invest (2005) 1.62
The DNA sequence and comparative analysis of human chromosome 5. Nature (2004) 1.62
Comparative genomic analysis as a tool for biological discovery. J Physiol (2004) 1.61
Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol (2003) 1.60
Directed evolution of ionizing radiation resistance in Escherichia coli. J Bacteriol (2009) 1.60
Lack of support for the association between GAD2 polymorphisms and severe human obesity. PLoS Biol (2005) 1.59
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest (2005) 1.58
Enhancer identification through comparative genomics. Semin Cell Dev Biol (2007) 1.56
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology (2003) 1.54
Perilipin, a potential substitute for adipophilin in triglyceride storage in human macrophages. Atherosclerosis (2006) 1.54
Identification of novel craniofacial regulatory domains located far upstream of SOX9 and disrupted in Pierre Robin sequence. Hum Mutat (2014) 1.53
In vivo characterization of a vertebrate ultraconserved enhancer. Genomics (2005) 1.49
Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis. Arterioscler Thromb Vasc Biol (2004) 1.48
PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH. Atherosclerosis (2011) 1.44
Implications of emerging risk factors for therapeutic intervention. Nutr Metab Cardiovasc Dis (2005) 1.43
Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis (2002) 1.41
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab (2007) 1.41
The sequence and analysis of duplication-rich human chromosome 16. Nature (2004) 1.38
Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest (2005) 1.37
Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem (2002) 1.36
Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.36
Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem (2003) 1.31
Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study. Hum Mol Genet (2008) 1.30
Array comparative genomic hybridization in patients with congenital diaphragmatic hernia: mapping of four CDH-critical regions and sequencing of candidate genes at 15q26.1-15q26.2. Eur J Hum Genet (2006) 1.29
Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta (2006) 1.26
Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol (2006) 1.26
Functional autonomy of distant-acting human enhancers. Genomics (2009) 1.25
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin (2004) 1.25